Amgen and UCB have released results from the fourth year of a Phase 2 study demonstrating the safety and efficacy of a second course of treatment with evenity (romosozumab), an investigational candidate for postmenopausal women with osteoporosis.
News from Twitter
Looking forward to meeting you all at #BIO2017 San Diego, June 19-22, 2017. Let's schedule: 1 (800) 445-1839 // +41 22 518 2100
Scopis launches mixed reality spinal surgery navigator with Microsoft’s HoloLens captis.com/scopis-la…
One Drop, MannKind ink partnership for connected, inhaled diabetes tech captis.com/?p=33587
Our very best and up-to-date selection of healthcare Industries' News (Products, Markets, Companies, R&D, Technology, Opportunities, Investment & Finance...).
Read at Healthcare News